Tomuzotuximab Completed Phase 2 Trials for Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02052960CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer